Vernalis spikes troubled V3381 program

The U.K'.s Vernalis says that interim data from a pilot study of V3381 for chronic cough along with the data from a Phase IIb study in neuropathic pain convinced the developer to spike any further plans to develop the therapy. Vernalis' shares were hammered back in March after the company announced that V3381 had flunked the IIb study. Once one of the U.K.'s biggest biotech companies, repeated clinical failures have steadily chipped away at its value. Vernalis release

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.